The U.S. Dept. of Defense awarded PerkinElmer Genetics a 16-month contract for newborn screening and supplies.
The deal is worth up to $9.7 million for the Bridgeville, Pa.-based PerkinElmer Inc. (NYSE:PKI) unit.
The Medical Device Business Journal — Medical Device News & Articles | MassDevice
The U.S. Dept. of Defense awarded PerkinElmer Genetics a 16-month contract for newborn screening and supplies.
The deal is worth up to $9.7 million for the Bridgeville, Pa.-based PerkinElmer Inc. (NYSE:PKI) unit.
PerkinElmer Inc. (NYSE:PKI) completed the offloading of its illumination and detection solutions business to a private equity firm for a half billion.
The unit went to Excelitas Technologies Corp., an affiliate of New York-based private equity firm Veritas Capital Fund III LP, and netted the Waltham, Mass.-based diagnostics and equipment giant $482 million, according to the company.
PerkinElmer Inc. (NYSE:PKI) plans to deal its illumination and detection solutions business to a private equity firm for a cool half billion.
The Waltham, Mass.-based diagnostics and equipment giant said it agreed to sell the IDS unit to Veritas Capital Fund III LP, a New York-based private equity firm, for a $482 million net.
PerkinElmer Inc. (NYSE:PKI) posted strong second-quarter results as its efforts to boost its profile and expand its geographic footprint bore fruit.
The Waltham, Mass.-based diagnostics giant reported revenues of $497.8 million for the three months ended July 4, up 13.6 percent compared with $438.3 million during the same period last year. Net income for the quarter rose 168 percent to $57.6 million, or 49 cents per diluted share, compared with $21.5 million, or 18 cents per diluted share, during Q2 2009.
PerkinElmer Inc. (NYSE:PKI) has acquired VisEn Medical Inc., an in vivo molecular imaging technology company based in Bedford, Mass of an undisclosed amount of money.
The Waltham Mass.-based diagnostics maker said it bought VisEn to offer more preclinical research tools to academic institutions and pharmaceutical companies.
Supported in part by the positive effects of foreign currency conversions and several recent acquisitions, PerkinElmer Inc. (NYSE:PKI) generated a $24.4 million net profit, or 21 cents per share, on $465.1 million in revenues during the three months ended April 4.
PerkinElmer Inc. (NYSE:PKI) agreed to buy Signature Genomic Laboratories LLC for an undisclosed sum.
The Waltham, Mass.-based diagnostics and lab equipment maker said it will acquire Spokane, Wash.-based Signature, which performs several types of screening for pre-natal and post-natal genetic diseases, as well as cytogenetic testing of chromosome abnormalities in individuals with unexplained physical and developmental disabilities.
PerkinElmer Inc. (NYSE:PKI) is expanding in India, opening a new lab facility to increase its ob/gyn and neo-natal screening capabilities on the sub-continent.
The Waltham, Mass.-based diagnostics and lab equipment maker said its new Health Sciences laboratory in Chennai, India, will offer its latest diagnostics tests for expectant mothers and newborns.
PerkinElmer also said it inked a deal with MediScan Systems, an Indian ultrasound clinic and training center.
Topping both analyst’s and its own prior estimates, adjusted fourth-quarter earnings at PerkinElmer Inc. (NYSE:PKI) rose handily despite a slight dip in revenues for the diagnostic and laboratory equipment maker.
Company executives said they were largely pleased with the results, noting that the Waltham, Mass.-based firm was able to top expectations in a tough market while also investing in several initiatives supporting future growth.
“We believe this balanced approach allowed us to exit 2009 stronger and better positioned strategically,” CEO Robert Friel said in a press release.
The administration chief for PerkinElmer Inc. (NYSE:PKI), Richard Walsh, plans to step down in March, according to a filing with the federal Securities and Exchange Commission.*
The Federal Trade Commission will force the sale of MDS Inc.’s (NYSE:MDZ) laser-microdissection unit to Life Technologies Corp. (NSDQ:LIFE) after Danaher Corp. (NYSE:DHR) completes its $650 million buyout of MDS.
The anti-trust watchdog wants to make sure that two of the four North American suppliers of the devices don’t wind up under the same corporate roof, according to Dow Jones Newswires.